Nucor earnings beat by $0.08, revenue fell short of estimates
CHELMSFORD, MA - Harte Hanks (NASDAQ:HHS), a $33.5 million market cap company specializing in customer experience and data-driven marketing, today announced the acquisition of exclusive licensing rights to a substantial health data asset from ADS Data Direct. According to InvestingPro data, the company maintains strong liquidity with assets exceeding short-term obligations, though it currently trades near its 52-week low of $4.24. The agreement grants Harte Hanks control over ADS’s Medical Ailment Database, which aligns with the company’s strategy to enhance its leadership in HIPAA-compliant, precision healthcare marketing.
The Medical Ailment Database, sourced from the Healthier Me Today platform, comprises self-reported information from consumers who have consented to share their health conditions, spanning over 200 categories. This partnership is expected to bolster Harte Hanks’ targeting capabilities and campaign performance for clients in the healthcare industry, including those in pharmaceuticals and medical devices. With annual revenue of $181.35 million, this strategic move could help improve the company’s financial performance. InvestingPro analysis shows 8 additional key insights about Harte Hanks’ financial health and market position.
Teresa Gavin, VP of Data Solutions at Harte Hanks, commented on the significance of this exclusive licensing deal. She emphasized the company’s reinforced ability to ethically engage consumers and deliver impactful results for healthcare marketers.
ADS Data Direct is recognized for its precision-targeted marketing solutions, and its Medical Ailment Database is noted for its depth and reliability. The database is designed to facilitate marketing campaigns directed at individuals with various health conditions, ensuring compliance with strict HIPAA regulations.
Eric Nelson, President & Managing Partner of ADS Data Direct, expressed confidence in Harte Hanks’ expertise to maximize the value of the data asset for healthcare marketers.
The acquisition of these licensing rights is a tactical move for Harte Hanks, marking a significant enhancement to its data solutions portfolio. While currently unprofitable, analysts tracked by InvestingPro expect the company to return to profitability this year, potentially benefiting from such strategic initiatives. This announcement is based on a press release statement from Harte Hanks. For further information, media inquiries can be directed to Cindy Stein, Global Head of Marketing at Harte Hanks. Discover comprehensive analysis and detailed metrics in the Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Harte Hanks Inc. reported the results of its 2025 Annual Meeting of Stockholders, where shareholders elected four nominees to the board of directors, including Genni Combes and John H. Griffin, Jr. The meeting also saw the approval of executive compensation packages, indicating shareholder satisfaction with the current pay structure. Additionally, the selection of Wolf & Company P.C. as the independent auditor for the fiscal year ending December 31, 2025, was ratified. In another development, Harte Hanks entered into a cooperation agreement with major shareholders Gary S. Rosenbach and Susan Rosenbach. This agreement includes standstill provisions and mutual non-disparagement clauses, with the Rosenbachs agreeing to vote in line with the Board’s recommendations until the 2026 annual meeting. The agreement remains effective as long as the Rosenbachs’ ownership stays above 10% of Harte Hanks’ common stock. These recent developments reflect Harte Hanks’ efforts to maintain a collaborative approach with its shareholders in corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.